Molecular Genetic Study of Mayer-Rokitansky-Kuster-Hauser Syndrome (MRKH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02967822|
Recruitment Status : Recruiting
First Posted : November 18, 2016
Last Update Posted : October 12, 2018
In order to understand the molecular mechanisms leading to Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH), the research team has to identify molecular bases of this anomaly.
Toward this goal, the research team would like to include in the study patients with MRKH syndrome, as well as their healthy relatives, in order to perform genetic analyses, especially whole exome sequencing.
This study has been set up in order to collect biological samples from patients with MRKH and their relatives.
|Condition or disease||Intervention/treatment|
|Mayer Rokitansky Kuster Hauser Syndrome||Genetic: Biological samples for patients Genetic: Biological samples for healthy relatives|
The MRKH is a congenital and rare malformation characterised by the absence of the uterus and of 2/3 of the vagina. The incidence is 1 in 4500 female children (46,XX) and a genetic component has been identified.
In order to understand the molecular mechanisms leading to this disease, the research team has to identify the genetic abnormalities.
This study will be led by the research team of the Imagine Institute and the clinical teams associated with the Reference Center for Rare Diseases PGR (Rare Gynecologic Diseases). Both groups are based on the Necker Hospital campus, and already closely collaborate on research into MRKH syndrome.
This collaboration will allow to :
i) collect biological samples from the propositus and their relatives,
ii) have a medical expertise.
The clinicians involved in the study will recruit patients, whose participation will involve providing a biological sample, ie, a blood sample and/or uterine tissue collected during surgical ablation, in the event that surgery is performed during clinical follow-up of the patients. No specific intervention will be planned for the purposes of this study.
In order to perform genetic analysis on trios, the healthy relatives of the patients (parents, brothers, sisters) will also be included. Blood samples will be taken once for healthy relatives.
Genetic analysis, especially whole exome sequencing, will be performed on blood samples by the research team of Imagine Institute.
|Study Type :||Observational|
|Estimated Enrollment :||410 participants|
|Official Title:||Etude de Génétique moléculaire du Syndrome de Mayer-Rokitansky-Kuster-Hauser|
|Study Start Date :||May 2016|
|Estimated Primary Completion Date :||May 2031|
|Estimated Study Completion Date :||May 2031|
Patients with MRKH syndrome
Biological samples for patients.
Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study.
Genetic: Biological samples for patients
Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
Biological samples for healthy relatives.
Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)
Genetic: Biological samples for healthy relatives
- Number of identified nucleotidic variation(s) whose consequences can explain the phenotype of MRKH syndrome [ Time Frame: 15 years ]Genetic cause identification
Biospecimen Retention: Samples With DNA
- Blood samples (for patients and healthy relatives)
- Uterine tissue (for patients who have a surgical intervention during their routine follow-up, and only if samples remain available after routine care analyses).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02967822
|Contact: Stanislas Lyonnet||+33 1 44 49 51 firstname.lastname@example.org|
|Contact: Anna Pelet||+33 1 42 75 43 email@example.com|
|Necker - Enfants malades hospital||Recruiting|
|Paris, France, 75015|
|Contact: Michel Polak firstname.lastname@example.org|
|Contact: Magali Viaud email@example.com|
|Institut Mutualiste Montsouris||Recruiting|
|Contact: Christine Louis-Sylvestre firstname.lastname@example.org|
|Study Director:||Stanislas Lyonnet||Institut Imagine|
|Principal Investigator:||Michel Polak||Necker - Enfants malades hospital|